These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

347 related items for PubMed ID: 15983549

  • 21. [Quadruple therapy with CsA, MTX, MMF and ATG for preventing graft-versus-host disease in unrelated donor hematopoietic stem cell transplantation].
    Liu QF, Sun J, Zhang Y, Xu D, Liu XL, Xu B, Meng FY, Zhou SY.
    Di Yi Jun Yi Da Xue Xue Bao; 2003 Nov; 23(11):1143-5. PubMed ID: 14625172
    [Abstract] [Full Text] [Related]

  • 22. Inferior Outcomes with Cyclosporine and Mycophenolate Mofetil after Myeloablative Allogeneic Hematopoietic Cell Transplantation.
    Hamilton BK, Liu Y, Hemmer MT, Majhail N, Ringden O, Kim D, Costa L, Stuart R, Alousi A, Pidala JA, Couriel DR, Aljurf M, Antin JH, Bredeson C, Cahn JY, Cairo M, Choi SW, Dandoy C, Gale RP, Gergis U, Hematti P, Inamoto Y, Kamble RT, MacMillan M, Marks DI, Nemecek E, Nishihori T, Saad A, Savani BN, Schriber J, Seo S, Socié G, Teshima T, Verdonck LF, Waller EK, Wirk M, Spellman SR, Arora M, Chhabra S.
    Biol Blood Marrow Transplant; 2019 Sep; 25(9):1744-1755. PubMed ID: 31158502
    [Abstract] [Full Text] [Related]

  • 23. [Study on graft-versus-host disease in the allogeneic peripheral blood stem cell transplantation for the treatment of leukemia].
    Zhang WP, Wang JM, Ju XP, Song XM, Tong SP, Li HM.
    Zhonghua Xue Ye Xue Za Zhi; 2003 Mar; 24(3):129-33. PubMed ID: 12697123
    [Abstract] [Full Text] [Related]

  • 24. [Mycophenolate mofetil in treatment of graft-versus-host disease after allogeneic hematopoietic cell transplantation: analysis of 44 cases].
    Chen H, Liu KY, Liu DH, Xu LP, Han W, Chen YH, Huang XJ.
    Zhonghua Yi Xue Za Zhi; 2008 Aug 05; 88(30):2127-30. PubMed ID: 19080474
    [Abstract] [Full Text] [Related]

  • 25. Unrelated donor granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell transplantation after nonmyeloablative conditioning: the effect of postgrafting mycophenolate mofetil dosing.
    Maris MB, Sandmaier BM, Storer BE, Maloney DG, Shizuru JA, Agura E, Kliem C, Pulsipher M, Maziarz RT, McSweeney PA, Wade J, Langston AA, Chauncey TR, Bruno B, Blume KG, Storb R.
    Biol Blood Marrow Transplant; 2006 Apr 05; 12(4):454-65. PubMed ID: 16545729
    [Abstract] [Full Text] [Related]

  • 26. Combined standard graft-versus-host disease (GvHD) prophylaxis with mycophenolate mofetil (MMF) in allogeneic peripheral blood stem cell transplantation from unrelated donors.
    Kasper C, Sayer HG, Mügge LO, Schilling K, Scholl S, Issa MC, Höffken K.
    Bone Marrow Transplant; 2004 Jan 05; 33(1):65-9. PubMed ID: 14704658
    [Abstract] [Full Text] [Related]

  • 27. Sirolimus and Mycophenolate Mofetil as Calcineurin Inhibitor-Free Graft-versus-Host Disease Prophylaxis for Reduced-Intensity Conditioning Umbilical Cord Blood Transplantation.
    Bejanyan N, Rogosheske J, DeFor TE, Lazaryan A, Arora M, Holtan SG, Jacobson PA, MacMillan ML, Verneris MR, Blazar BR, Weisdorf DJ, Wagner JE, Brunstein CG.
    Biol Blood Marrow Transplant; 2016 Nov 05; 22(11):2025-2030. PubMed ID: 27519278
    [Abstract] [Full Text] [Related]

  • 28. [Prophylaxis of acute graft-versus-host disease after allogeneic bone marrow transplantation by mycophenolate mofetil in a murine model].
    Huang H, Zheng W, Lin M, Fu J, Zhang R.
    Zhonghua Xue Ye Xue Za Zhi; 2002 Apr 05; 23(4):191-3. PubMed ID: 12133455
    [Abstract] [Full Text] [Related]

  • 29. A pilot study of tacrolimus and mycophenolate mofetil graft-versus-host disease prophylaxis in childhood and adolescent allogeneic stem cell transplant recipients.
    Osunkwo I, Bessmertny O, Harrison L, Cheung YK, Van de Ven C, del Toro G, Garvin J, George D, Bradley MB, Wolownik K, Wischhover C, Levy J, Skerrett D, Cairo MS.
    Biol Blood Marrow Transplant; 2004 Apr 05; 10(4):246-58. PubMed ID: 15077223
    [Abstract] [Full Text] [Related]

  • 30. The combination of cyclosporine and mycophenolate mofetil is less effective than cyclosporine and methotrexate in the prevention of acute graft-versus host disease after stem-cell transplantation from unrelated donors.
    Yerushalmi R, Shem-Tov N, Danylesko I, Shouval R, Nagler A, Shimoni A.
    Am J Hematol; 2017 Mar 05; 92(3):259-268. PubMed ID: 28052467
    [Abstract] [Full Text] [Related]

  • 31. Imatinib combined with myeloablative allogeneic hematopoietic stem cell transplantation for advanced phases of chronic myeloid leukemia.
    Luo Y, Zhao Y, Tan Y, Shi J, Han X, Zheng Y, Li L, He J, Xie W, Ye X, Cai Z, Lin M, Huang H.
    Leuk Res; 2011 Oct 05; 35(10):1307-11. PubMed ID: 21354617
    [Abstract] [Full Text] [Related]

  • 32. Mycophenolate mofetil and cyclosporine for graft-versus-host disease prophylaxis following reduced intensity conditioning allogeneic stem cell transplantation.
    Mohty M, de Lavallade H, Faucher C, Bilger K, Vey N, Stoppa AM, Gravis G, Coso D, Viens P, Gastaut JA, Blaise D.
    Bone Marrow Transplant; 2004 Sep 05; 34(6):527-30. PubMed ID: 15286687
    [Abstract] [Full Text] [Related]

  • 33. [Combination of mycophenolate mofetil with cyclosporine A and methotrexate as acute GVHD prophylaxis after unrelated donor allogeneic bone marrow transplantation].
    Huang H, Lin M, Meng H, Qian W, Jin J, Huang J, Luo Y.
    Zhonghua Xue Ye Xue Za Zhi; 2001 Feb 05; 22(2):76-8. PubMed ID: 11877053
    [Abstract] [Full Text] [Related]

  • 34. Use of mycophenolate mofetil and a calcineurin inhibitor in allogeneic hematopoietic stem-cell transplantation from HLA-matched siblings or unrelated volunteer donors: Japanese multicenter phase II trials.
    Nakane T, Nakamae H, Yamaguchi T, Kurosawa S, Okamura A, Hidaka M, Fuji S, Kohno A, Saito T, Aoyama Y, Hatanaka K, Katayama Y, Yakushijin K, Matsui T, Yamamori M, Takami A, Hino M, Fukuda T.
    Int J Hematol; 2017 Apr 05; 105(4):485-496. PubMed ID: 27943166
    [Abstract] [Full Text] [Related]

  • 35. The combination of sirolimus plus tacrolimus improves outcome after reduced-intensity conditioning, unrelated donor hematopoietic stem cell transplantation compared with cyclosporine plus mycofenolate.
    Perez-Simón JA, Martino R, Parody R, Cabrero M, Lopez-Corral L, Valcarcel D, Martinez C, Solano C, Vazquez L, Márquez-Malaver FJ, Sierra J, Caballero D.
    Haematologica; 2013 Apr 05; 98(4):526-32. PubMed ID: 23065527
    [Abstract] [Full Text] [Related]

  • 36. Enteric-coated mycophenolate sodium containing GvHD prophylaxis reduces GvHD rate after allogeneic HSCT.
    Weber T, Niestadtkötter J, Wienke A, Müller-Tidow C, Müller LP.
    Eur J Haematol; 2016 Sep 05; 97(3):232-8. PubMed ID: 26613546
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Higher Dose of Mycophenolate Mofetil Reduces Acute Graft-versus-Host Disease in Reduced-Intensity Conditioning Double Umbilical Cord Blood Transplantation.
    Bejanyan N, Rogosheske J, DeFor T, Lazaryan A, Esbaum K, Holtan S, Arora M, MacMillan ML, Weisdorf D, Jacobson P, Wagner J, Brunstein CG.
    Biol Blood Marrow Transplant; 2015 May 05; 21(5):926-33. PubMed ID: 25655791
    [Abstract] [Full Text] [Related]

  • 40. Mycophenolate mofetil use after unrelated hematopoietic stem cell transplantation for prophylaxis and treatment of graft-vs.-host disease in adult patients in Japan.
    Iida M, Fukuda T, Uchida N, Murata M, Aotsuka N, Minagawa K, Oohashi K, Fukushima K, Kondo T, Eto T, Miyamoto T, Morishima Y, Nagamura T, Atsuta Y, Suzuki R.
    Clin Transplant; 2014 Sep 05; 28(9):980-9. PubMed ID: 24943923
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.